U.S. CDMRP – Breast Cancer Research Program | Research Funding


Event details

Date 28.03.2023
Category Call for proposal
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Breast Cancer Research Program (BCRP) Awards. Several award programs are available:
  • The Breakthrough Awards supports promising research that has high potential to lead to or make breakthroughs in breast cancer. The Breakthrough Award is structured with four different funding levels. Each level has a defined research scope :
    • Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem.
    • Funding Level 2: Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.
    • Funding Level 3: Advanced translational studies with a high degree of project readiness.
    • Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required.
  • The Clinical Research Extension Award aims to extend the data collection, follow-up, and analysis of breast cancer clinical research studies. Proposed research may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial.
  • The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s)
  • The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer.

All applications for BCRP funding must specifically address at least one of the Overarching Challenges as directed by Congress and have direct relevance to military health. The FY23 BCRP Challenges are listed at the end of this announcement.

Funding:       Breakthrough 1 – $450K - $750K
Breakthrough 2 – $1M - $1.5M
Breakthrough 3 – $4M - $5M
Breakthrough 4 – max. $15M
Clinical Research Extension – $5M - $6M
Era of Hope – max. $3M
Innovator – max. $7M

Duration:      Breakthrough 1 – 3 years
Breakthrough 2 – 3-4 years
Breakthrough 3 – 4 years
Breakthrough 4 – 4 years
Clinical Research Extension – 4 years
Era of Hope – 4 years
Innovator – 4 years

Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible for the Breakthrough Awards and Clinical Research Extension Awards. All investigators at or above the level of assistant professor (or equivalent) are eligible for the Era of Hope Awards. All investigators at or above the level of associate professor (or equivalent) are eligible for the Innovator Awards.

How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace. Application packages can be downloaded from Grants.gov at any time.

Grants.gov Funding Opportunity Numbers:
Pre-Application Deadline:           (1) 5:00 p.m. Eastern time (ET), March 28, 2023
(2) 5:00 p.m. Eastern time (ET), March 29, 2023
Full Application Deadline:            program-dependent

Further information
  • To find the full program announcements, use the opportunity-specific links above to connect to Grants.gov
  • For questions about the eBRAP or Grants.gov platforms, contact the Research Office.

FY23 BCRP Overarching Challenges:
  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of overdiagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
  • Eliminate the mortality associated with metastatic breast cancer

Practical information

  • General public
  • Free


Event broadcasted in